CD68 and chronic obstructive pulmonary disease: A randomised placebo-controlled study of stable COPD demonstrated that cilomilast reduces the numbers of bronchial tissue CD8+ (T-cytotoxic) and CD68+ (macrophages) inflammatory cells, cells considered to be key players in the pathogenesis of COPD [27].